



**Maidstone and
Tunbridge Wells**
NHS Trust

Ref: FOI/GS/ID 6241

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net

02 December 2020

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to atopic dermatitis.

You asked:

1. How many patients were treated within your Trust with the following drugs within the specified time periods?

Number of patients treated between 01 February 2017 and 31 July 2018

Number of patients treated between 01 August 2018 and 31 January 2020

Apremilast

Adalimumab

Dupilumab

Etanercept

Infliximab

Secukinumab

Ustekinumab

2. How many patients were treated within your Trust for atopic dermatitis within the specified time periods?

Number of patients treated for atopic dermatitis between 01 February 2017 and 31 July 2018

Number of patients treated for atopic dermatitis between 01 August 2018 and 31 January 2020

3. How many patients were treated within your Trust with the following drugs for atopic dermatitis within the specified time periods?

Number of patients treated for atopic dermatitis between 01 February 2017 and 31 July 2018

Number of patients treated for atopic dermatitis between 01 August 2018 and 31 January 2020

Apremilast

Adalimumab

Dupilumab

Etanercept

Infliximab
 Secukinumab
 Ustekinumab

4. Please specify how patients treated with the following drugs are coded (OPCS code) within your trust:

OPCS code (e.g. X385 subcutaneous immunotherapy)

Apremilast
 Adalimumab
 Dupilumab
 Etanercept
 Infliximab
 Secukinumab
 Ustekinumab

5. Please provide the number of patients treated in the homecare setting for atopic dermatitis within the specified time periods:

Number of patients treated in the homecare setting for atopic dermatitis between 01 February 2017 and 31 July 2018

Number of patients treated in the homecare setting for atopic dermatitis between 01 August 2018 and 31 January 2020

6. How many of your Trust's homecare patients were treated with the following drugs for atopic dermatitis within the specified time periods?

Number of patients treated for atopic dermatitis between 01 February 2017 and 31 July 2018

Trust response:

1.	01/02/2017-31/07/2018	01/08/2018-31/01/2020
adalimumab	474	645
apremilast	4	3
Etanercept	312	307
infliximab	264	257
secukinumab	45	109
ustekinumab	18	52

2. We do not have a dermatology service.

3. We do not have a dermatology service.

4. These would have been coded using the High cost Drugs list:

Apremilast	X92.1
Adalimumab	X92.1
Etanercept	X92.1
Infliximab	X92.1
Secukinumab	X92.1
Ustekinumab	X89.1

Dupilumab is not on the list of High cost drugs and would be coded to the route of delivery X38.5 Subcutaneous immunotherapy

5. We do not have a dermatology service.